Abstract:BackgroundThere is an urgent need for new treatments for platinum-resistant recurrent ovarian cancer (PROC). Addition of bevacizumab (bev) to non-platinum-based chemotherapy (chemo) significantly improved PFS in patients (pts) with PROC but did not show a clear OS benefit. Thus far, the combination of paclitaxel + bev has shown the most promise in PROC, although the proportion of pts eligible for bev is limited by treatment-related toxicities. Combination of the anti-PD-1 antibody pembrolizumab (pembro) with weekly paclitaxel showed antitumor activity and manageable toxicity in pts with PROC in a single-arm, phase II study. ENGOT-ov65/KEYNOTE-B96 (NCT05116189) compares the efficacy and safety of pembro + standard of care chemo (weekly paclitaxel) ± bev vs placebo (pbo) + weekly paclitaxel ± bev in pts with PROC.Trial designIn this randomized, pbo-controlled, double-blind, phase III study, eligible pts are aged ≥18 y with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1-2 prior lines of systemic therapy, including ≥1 prior platinum-based therapy with ≥4 cycles in first line. Pts must have platinum-resistant disease (radiographic evidence of PD ≤6 mo after last platinum-based therapy dose), be eligible for paclitaxel (± bev per investigator discretion), have ECOG PS ≤1, radiographically evaluable disease per RECIST v1.1, and have a tumor sample for central evaluation of PD-L1 status. ∼616 pts will be randomized 1:1 to pembro 400 mg IV or pbo Q6W for up to 18 cycles (∼2 y) + paclitaxel 80 mg/m2 on days 1, 8, and 15 of each Q3W cycle (± bev 10 mg/kg Q2W per investigator discretion) until PD or unacceptable toxicity. Randomization is stratified by planned bev use (yes vs no), region (US vs Europe vs rest of world), and PD-L1 status (combined positive score [CPS] <1 vs CPS 1-<10 vs CPS ≥10). Primary endpoint is PFS per RECIST v1.1 by investigator review in pts with tumor PD-L1 CPS ≥1 and in all pts. Secondary endpoints are OS in pts with tumor PD-L1 CPS ≥1 and in all pts, PFS per RECIST v1.1 by blinded independent central review in pts with tumor PD-L1 CPS ≥1 and in all pts, safety, and pt-reported outcomes. Enrollment is ongoing.Clinical trial identificationNCT05116189.Legal entity responsible for the studyMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.FundingMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.DisclosureN. Colombo: Financial Interests, Personal, Full or part-time Employment, Employment of Immediate Family Member: Sarepta Therapeutics; Financial Interests, Personal, Advisory Role: Roche/Genentech, AstraZeneca, Clovis Oncology, Pfizer, MSD Oncology, Tesaro, GlaxoSmithKline, Immunogen, Mersana, Eisai, Advaxis, Nuvation Bio, Advaxis; Financial Interests, Personal, Other, Honoraria: Roche/Genentech, AstraZeneca, Tesaro, GlaxoSmithKline, MSD Oncology, Clovis Oncology, Pfizer, Amgen, Immunogen, Novartis, Pfizer, Mersana, Eisai, Advaxis, Nuvation Bio. R.L. Coleman: Financial Interests, Personal, Full or part-time Employment: US Oncology; Financial Interests, Personal, Advisory Role: Clovis Oncology, Genentech/Roche, AstraZeneca/MedImmune, Genmab, Tesaro, OncoMed, Sotio, Oncolytics, AbbVie/Stemcentrx, Immunogen, AbbVie, Agenus, Novocure, Merck, OncXerna Therapeutics, Alkermes, Gradalis, Regeneron; Financial Interests, Personal, Leadership Role: Onxeo; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck, AstraZeneca/MedImmune, Array BioPharma, Clovis Oncology, Roche/Genentech, Research to Practice, GOG Foundation, Sotio, Vaniam Group; Financial Interests, Personal, Stocks/Shares: McKesson; Financial Interests, Personal, Ownership Interest: McKesson; Financial Interests, Personal, Research Grant: AstraZeneca/MedImmune, Esperance Pharmaceuticals, Array Biopharma, Clovis Oncology, Johnson & Johnson, Merck, Roche/Genentech, Abbott/AbbVie; Financial Interests, Institutional, Research Grant: Immunogen, Mirati Therapeutics, Amgen, Pfizer, Lilly, Regeneron. F. Kose: Financial Interests, Personal, Advisory Role: Roche, AstraZeneca, MSD/Merck, GlaxoSmithKline, Novartis, Pfizer, Takeda, Deva, Nobel, Astellas, Janssen; Financial Interests, Institutional, Other, Honoraria: Roche, AstraZeneca, MSD/Merck, GlaxoSmithKline, Novartis, Pfizer, Takeda, Deva, Nobel, Astellas, Janssen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Roche, AstraZeneca, MSD/Merck, GlaxoSmithKline, Novartis, Pfizer, Takeda, Deva, Nobel, Astellas, Janssen. R. Wenham: Financial Interests, Personal, Advisory Role: Mersana, Merck, Tesaro, Clovis Oncology, Genentech, Regeneron, AbbVie, AstraZeneca, GlaxoSmithKline, Seattle Genetics/Astellas, Legend Biotech; Financial Interests, Personal, Speaker's Bureau: Tesaro, Clovis Oncology, Genentech; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: TapImmune Inc; Financial Interests, Personal, Stocks/Shares: Ovation Diagnostics; Financial Interests, Personal, Ownership Interest: Ovation Diagnostics; Financial Interests, Personal, Other, Honoraria: Tesaro, Seattle Genetics; Financial Interests, Institutional, Research Grant: Merck, Prescient Therapeutics, Anixa Biosciences. Other Relationship: AstraZeneca, GlaxoSmithKline/Tesaro; Other, Personal, Other: AstraZeneca, GlaxoSmithKline/Tesaro. A. Sebastianelli: Financial Interests, Personal, Advisory Role: AstraZeneca, Merck, GlaxoSmithKline; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Merck, GlaxoSmithKline. K. Hasegawa: Financial Interests, Personal, Advisory Role: MSD K.K., Kaken Pharmaceutical, Eisai, Takeda; Financial Interests, Personal, Other, Honoraria: MSD K.K., Daiichi Sankyo, Chugai Pharma, AstraZeneca, Eisai, Kyowa Kirin, Takeda, Genmab; Financial Interests, Personal, Research Grant: Ono Pharmaceutical, Daiichi Sankyo, Merck, Takeda, Eisai. E. Zsiros: Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Other, Honoraria: Survivornet, AstraZeneca, TeneoBio; Financial Interests, Personal, Research Grant: Merck. T. De La Motte Rouge: Financial Interests, Personal, Other, Honoraria: AstraZeneca, MSD/Merck, Clovis Oncology, Tesaro, GlaxoSmithKline, Pfizer, Gilead Sciences, Eisai, French National Cancer Institute (INCa); Financial Interests, Personal, Advisory Role: AstraZeneca, MSD/Merck, Clovis Oncology, Tesaro, GlaxoSmithKline, Pfizer, Gilead Sciences, Eisai, French National Cancer Institute (INCa); Financial Interests, Institutional, Research Grant: Pfizer, Novartis, Seagen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: AstraZeneca, MSD/Merck, Clovis Oncology, Tesaro, GlaxoSmithKline, Pfizer, Gilead Sciences, French National Cancer Institute (INCa). M. Bidzinski: Financial Interests, Personal, Other, Honoraria: AstraZeneca, MSD/Merck, GlaxoSmithKline, Johnson & Johnson, Olympus. I. McNeish: Financial Interests, Personal, Advisory Role: Clovis Oncology, AstraZeneca, Carrick Therapeutics, Roche, BeiGene, Scancell Ltd., GlaxoSmithKline, Epsila; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: AstraZeneca; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca. J. Sehouli: Financial Interests, Personal, Advisory Role: AstraZeneca, Clovis Oncology, PharmaMar, Merck, Pfizer, Tesaro, MSD Oncology, Lilly, Novocure, Johnson & Johnson, Roche, Ingress Health, Riemser, Sobi, GlaxoSmithKline, Novartis; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: AstraZeneca, Clovis Oncology, PharmaMar, Roche Pharma AG, Tesaro, MSD Oncology, Olympus; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Eisai, Clovis Oncology, Olympus Medical Systems, Johnson & Johnson, PharmaMar, Pfizer, Teva, Tesaro, MSD Oncology, GlaxoSmithKline, Bayer; Financial Interests, Institutional, Research Grant: AstraZeneca, Clovis Oncology, Merck, Bayer, PharmaMar, Pfizer, Tesaro, MSD Oncology, Roche. J. Korach: Financial Interests, Institutional, Research Grant: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. P.R. Debruyne: Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Janssen; Financial Interests, Personal, Stocks/Shares: Alkermes, Biocartis Group NV; Financial Interests, Personal, Ownership Interest: Alkermes, Biocartis Group NV; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb, Merck/Pfizer, MSD, Roche, Bayer. J. Kim: Financial Interests, Personal, Advisory Board: Takeda Korea, GSK Korea, Boryung, Vifor Pharma, MSD Korea; Financial Interests, Personal, Invited Speaker: CMIC, AstraZeneca, Janssen; Financial Interests, Personal, Expert Testimony: LG Pharma. A.C. De Melo: Financial Interests, Personal, Speaker's Bureau: BMS Brazil, MSD Oncology; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: MSD Oncology; Financial Interests, Personal, Other, Honoraria: MSD Oncology, Novartis, BMS Brazil; Financial Interests, Institutional, Research Grant: Roche, MSD Oncology, BMS Brazil, Novartis, Clovis Oncology, AstraZeneca. X. Peng: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. A.M. Bogusz: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Ownership Interest: Merck & Co., Inc., Kenilworth, NJ, USA. K. Yamada: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Ownership Interest: Merck & Co., Inc., Kenilworth, NJ, USA. B.J. Monk: Financial Interests, Personal, Advisory Role: Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Myriad Pharmaceuticals, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, Tesa; Financial Interests, Personal, Leadership Role: US Oncology; Financial Interests, Personal, Speaker's Bureau: Roche/Genentech, AstraZeneca, Clovis Oncology, Eisai, Tesaro/GlaxoSmithKline, Merck; Financial Interests, Personal, Other, Honoraria: Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, Tesaro/GlaxoSmithKline, Vascular Biogenics; Financial Interests, Institutional, Research Grant: Novartis, Amgen, Genentech, Lilly, Janssen, Array BioPharma, Tesaro, Morphotek, Pfizer, Advaxis, AstraZeneca, Immunogen, Regeneron, Nucana. All other authors have declared no conflicts of interest. BackgroundThere is an urgent need for new treatments for platinum-resistant recurrent ovarian cancer (PROC). Addition of bevacizumab (bev) to non-platinum-based chemotherapy (chemo) significantly improved PFS in patients (pts) with PROC but did not show a clear OS benefit. Thus far, the combination of paclitaxel + bev has shown the most promise in PROC, although the proportion of pts eligible for bev is limited by treatment-related toxicities. Combination of the anti-PD-1 antibody pembrolizumab (pembro) with weekly paclitaxel showed antitumor activity and manageable toxicity in pts with PROC in a single-arm, phase II study. ENGOT-ov65/KEYNOTE-B96 (NCT05116189) compares the efficacy and safety of pembro + standard of care chemo (weekly paclitaxel) ± bev vs placebo (pbo) + weekly paclitaxel ± bev in pts with PROC. There is an urgent need for new treatments for platinum-resistant recurrent ovarian cancer (PROC). Addition of bevacizumab (bev) to non-platinum-based chemotherapy (chemo) significantly improved PFS in patients (pts) with PROC but did not show a clear OS benefit. Thus far, the combination of paclitaxel + bev has shown the most promise in PROC, although the proportion of pts eligible for bev is limited by treatment-related toxicities. Combination of the anti-PD-1 antibody pembrolizumab (pembro) with weekly paclitaxel showed antitumor activity and manageable toxicity in pts with PROC in a single-arm, phase II study. ENGOT-ov65/KEYNOTE-B96 (NCT05116189) compares the efficacy and safety of pembro + standard of care chemo (weekly paclitaxel) ± bev vs placebo (pbo) + weekly paclitaxel ± bev in pts with PROC. Trial designIn this randomized, pbo-controlled, double-blind, phase III study, eligible pts are aged ≥18 y with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1-2 prior lines of systemic therapy, including ≥1 prior platinum-based therapy with ≥4 cycles in first line. Pts must have platinum-resistant disease (radiographic evidence of PD ≤6 mo after last platinum-based therapy dose), be eligible for paclitaxel (± bev per investigator discretion), have ECOG PS ≤1, radiographically evaluable disease per RECIST v1.1, and have a tumor sample for central evaluation of PD-L1 status. ∼616 pts will be randomized 1:1 to pembro 400 mg IV or pbo Q6W for up to 18 cycles (∼2 y) + paclitaxel 80 mg/m2 on days 1, 8, and 15 of each Q3W cycle (± bev 10 mg/kg Q2W per investigator discretion) until PD or unacceptable toxicity. Randomization is stratified by planned bev use (yes vs no), region (US vs Europe vs rest of world), and PD-L1 status (combined positive score [CPS] <1 vs CPS 1-<10 vs CPS ≥10). Primary endpoint is PFS per RECIST v1.1 by investigator review in pts with tumor PD-L1 CPS ≥1 and in all pts. Secondary endpoints are OS in pts with tumor PD-L1 CPS ≥1 and in all pts, PFS per RECIST v1.1 by blinded independent central review in pts with tumor PD-L1 CPS ≥1 and in all pts, safety, and pt-reported outcomes. Enrollment is ongoing. In this randomized, pbo-controlled, double-blind, phase III study, eligible pts are aged ≥18 y with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1-2 prior lines of systemic therapy, including ≥1 prior platinum-based therapy with ≥4 cycles in first line. Pts must have platinum-resistant disease (radiographic evidence of PD ≤6 mo after last platinum-based therapy dose), be eligible for paclitaxel (± bev per investigator discretion), have ECOG PS ≤1, radiographically evaluable disease per RECIST v1.1, and have a tumor sample for central evaluation of PD-L1 status. ∼616 pts will be randomized 1:1 to pembro 400 mg IV or pbo Q6W for up to 18 cycles (∼2 y) + paclitaxel 80 mg/m2 on days 1, 8, and 15 of each Q3W cycle (± bev 10 mg/kg Q2W per investigator discretion) until PD or unacceptable toxicity. Randomization is stratified by planned bev use (yes vs no), region (US vs Europe vs rest of world), and PD-L1 status (combined positive score [CPS] <1 vs CPS 1-<10 vs CPS ≥10). Primary endpoint is PFS per RECIST v1.1 by investigator review in pts with tumor PD-L1 CPS ≥1 and in all pts. Secondary endpoints are OS in pts with tumor PD-L1 CPS ≥1 and in all pts, PFS per RECIST v1.1 by blinded independent central review in pts with tumor PD-L1 CPS ≥1 and in all pts, safety, and pt-reported outcomes. Enrollment is ongoing. Clinical trial identificationNCT05116189. NCT05116189. Legal entity responsible for the studyMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. FundingMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Abstract:Background Despite treatment advances, gastric cancer (GC) remains a leading cause of cancer-related death worldwide. Standard first-line chemotherapeutic regimen for advanced GC consists of fluoropyrimidine with platinum-based combinations, such as capecitabine + oxaliplatin (CAPOX). Recently, CLDN18.2 has emerged as a promising targetable biomarker. In healthy tissue, CLDN18.2 is confined to gastric mucosa tight junctions. Upon malignant transformation, cell polarity perturbations lead to exposure of CLDN18.2 on the cell surface. Zolbetuximab is a chimeric IgG1 monoclonal antibody that specifically binds to CLDN18.2 and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. In a randomized phase II study (NCT01630083), patients (pts) with CLDN18.2+advanced GC/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) showed prolonged survival compared to EOX alone. Trial design This global, phase III, double-blind, placebo-controlled study (NCT03653507) will enroll ∼500 adult pts with CLDN18.2+/HER2– locally advanced unresectable or metastatic GC or GEJ not previously treated with chemotherapy for advanced/metastatic disease. Patients will be randomized 1:1 to receive zolbetuximab + CAPOX or placebo + CAPOX. Zolbetuximab will be administered by IV infusion as an 800 mg/m2 loading dose (Cycle 1, Day 1) followed by 600 mg/m2 Q3W in combination with CAPOX. Tumor tissue will be collected at screening to determine CLDN18.2 and HER2 status (if unknown) by central testing; pts will be considered CLDN18.2+ if ≥ 75% of tumor cells demonstrate moderate-to-strong membranous IHC staining. The primary objective is to compare progression-free survival of zolbetuximab + CAPOX vs placebo + CAPOX; secondary efficacy objectives include comparison of overall survival, objective response rate, and duration of response. The safety/tolerability profile, effects on health-related quality-of-life, PK profile, and immunogenicity of zolbetuximab are other secondary endpoints. Clinical trial identification NCT03653507. Editorial acknowledgement Patrick Tucker of OPEN Health Medical Communications. Legal entity responsible for the study Astellas Pharma, Inc. Funding Astellas Pharma, Inc. Disclosure J.A. Ajani: Advisory / Consultancy, Research grant / Funding (self): Astellas. S. Al-Batran: Advisory / Consultancy: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Servier; Speaker Bureau / Expert testimony: Nordic Bioscience; Research grant / Funding (institution): Hospira; Research grant / Funding (institution): Medac; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Vifor Pharma; Research grant / Funding (self): Roche Pharma AG. Y. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Taiho; Advisory / Consultancy: Daiich-Sankyo; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): FivePrime; Research grant / Funding (institution): Curis; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Ono; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BieGene; Advisory / Consultancy, Research grant / Funding (institution): GreenCross; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Advisory / Consultancy: Samyang Biopharm; Advisory / Consultancy: Hanmi; Research grant / Funding (institution): CKD Pharma. D.V. Catenacci: Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self): Gritstone; Honoraria (self), Advisory / Consultancy: Taiho; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo. P. Enzinger: Advisory / Consultancy: Merck; Advisory / Consultancy: Astellas; Advisory / Consultancy: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: Loxo; Advisory / Consultancy: Taiho. D. Ilson: Advisory / Consultancy: Astellas. S. Kim: Honoraria (self): Merck. F. Lordick: Honoraria (self): Astellas; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self): AstraZeneca; Advisory / Consultancy: Biontech; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self): Elsevier; Travel / Accommodation / Expenses: Infomedica; Honoraria (self): Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self): Servier; Honoraria (self): Amgen; Honoraria (self): Nordic Group; Honoraria (self): Ganymed Pharma; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Fresenius Biotech; Travel / Accommodation / Expenses: Taiho Pharma. K. Shitara: Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy: BMS; Advisory / Consultancy: Takeda; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (institution): Novartis; Honoraria (institution): AbbVie; Honoraria (institution): Yakult; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Chugai pharma; Advisory / Consultancy, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Medi Science. E. Van Cutsem: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy: Incyte; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen. A. Arozullah: Full / Part-time employment: Astellas Pharma Global Development. J.W. Park: Full / Part-time employment: Astellas Pharma Global Development. All other authors have declared no conflicts of interest.

KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Pemetrexed and Platinum with or Without Pembrolizumab for Tyrosine Kinase Inhibitor (Tki)-Resistant, EGFR-mutant, Metastatic Nonsquamous NSCLC: Phase 3 KEYNOTE-789 Study

ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 Study of Pembrolizumab or Placebo in Combination with Adjuvant Chemotherapy With/without Radiotherapy in Patients with Newly Diagnosed High-Risk Endometrial Cancer.

44Tip ENGOT-ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study of Pembrolizumab Vs Placebo + Paclitaxel with Optional Bevacizumab for Platinum-Resistant Recurrent Ovarian Cancer

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

Abstract CT555: Pembrolizumab Vs Chemotherapy in Chinese Patients with PD-L1-positive NSCLC: 4-Year Update from KEYNOTE-042 China Study

Pembrolizumab Vs Chemotherapy in Patients with Advanced/metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus As Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract OT1-18-06: KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Abstract CT282: KEYNOTE-975: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Pembrolizumab Vs Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

GLOW: Randomized Phase III Study of Zolbetuximab + CAPOX Compared with Placebo + CAPOX As First-Line Treatment of Patients with CLD18.2+/HER2− Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Pembrolizumab Plus Chemotherapy in Japanese Patients With Persistent, Recurrent or Metastatic Cervical Cancer: Results From KEYNOTE‐826

P-280 Pembrolizumab Versus Physician-Choice Chemotherapy for Previously Treated Patients with Advanced/metastatic Squamous or Adenocarcinoma of the Esophagus or Siewert I Adenocarcinoma of the Esophagogastric Junction (EGJ): Randomized, Phase 3 KEYNOTE-18